Douglas T Fearon from 4 Lloyd Point Dr, Hunt, NY 11743, age 82, Phone: 631 423-3560

Wikipedia References

Douglas Fearon

About:

Born:

1942

Work:

He is a fellow of the Royal Society and a member of the United States National Academy of Sciences.

Education:

Academic degree:

Member of the United States National Academy of Sciences

Area of science:

Immunology

Specialty:

Immunologist

Skills & Activities:

Ascribed status:

Fellow of the Royal Society • Fellow of the Royal College of Physicians • Fellow of the Academy of Medical Sciences

Douglas Fearon

Us Patents

Soluble Complement Regulatory Molecules
view source
US Patent:

6458360, Oct 1, 2002
Filed:

Dec 28, 1992
Appl. No.:

07/949472
Inventors:

Douglas T. Fearon - Baltimore MD
Thomas Hebell - Goettingen, DE
Assignee:

The Johns Hopkins University - Baltimore MD
International Classification:

A61K 39395
US Classification:

42419511, 4241921, 4241941, 435 697, 435 696, 530350, 5303873, 530395, 530402
Abstract:

This invention is directed to a soluble recombinant fused protein which is stable in the mammalian circulatory system comprising a polypeptide which contains a recognition site for a target molecule, such as a complement receptor site, and is joined to the N-terminal end of an immunoglobulin chain. The invention is also directed to a construct comprising a plurality of peptides containing short consensus repeats having a complement binding site attached to a soluble, physiologically compatible, macromolecular carrier. The invention is particularly useful for inhibiting complement activation or complement-dependent cellular activation in mammals.

Compositions Of Soluble Complement Receptor 1 (Cr1) And A Thrombolytic Agent, And The Methods Of Use Thereof
view source
US Patent:

52566420, Oct 26, 1993
Filed:

Sep 24, 1990
Appl. No.:

7/588128
Inventors:

Douglas T. Fearon - Baltimore MD
Lloyd B. Klickstein - Brookline MA
Winnie W. Wong - Newton MA
Gerald R. Carson - Wellesley MA
Michael F. Concino - Newton MA
Stephen H. Ip - Sudbury MA
C. Makrides; Savvas - Bedford MA
Henry C. Marsh - Reading MA
Assignee:

The Johns Hopkins University - Baltimore MD
Brigham and Women's Hospital - Boston MA
T Cell Sciences, Inc. - Cambridge MA
International Classification:

A61K 3702
A61K 37547
C12N 972
C07K 1300
US Classification:

514 8
Abstract:

The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention further relates to methods for treating thrombotic conditions in humans and animals by administering a composition comprising soluble CR1 and a thrombolytic agent. In particular, the compositions and methods are useful both for reducing reperfusion injury and ameliorating the other effects of myocardial infarction.

Human C3B/C4B Receptor (Cr1)
view source
US Patent:

59814810, Nov 9, 1999
Filed:

Jun 6, 1995
Appl. No.:

8/470652
Inventors:

Douglas T. Fearon - Baltimore MD
Lloyd B. Klickstein - Brookline MA
Winnie W. Wong - Newton MA
Gerald R. Carson - Wellesley MA
Michael F. Concino - Newton MA
Stephen H. Ip - Sudbury MA
Savvas C. Makrides - Bedford MA
Henry C. Marsh - Reading MA
Assignee:

The Johns Hopkins University - Baltimore MD
The Brigham & Women's Hospital - Boston MA
Avant Immunotherapeutics, Inc. - Needham MA
International Classification:

A61K 3818
C07K 1446
C12P 2100
US Classification:

514 12
Abstract:

The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

Human C3B/C4B Receptor (Cr1)
view source
US Patent:

58562974, Jan 5, 1999
Filed:

Jun 6, 1995
Appl. No.:

8/472038
Inventors:

Douglas T. Fearon - Baltimore MD
Lloyd B. Klickstein - Brookline MA
Winnie W. Wong - Newton MA
Gerald R. Carson - Wellesley MA
Michael F. Concino - Newton MA
Stephen H. Ip - Sudbury MA
Savvas C. Makrides - Bedford MA
Henry C. Marsh - Reading MA
Assignee:

The Johns Hopkins University - Baltimore MD
Brigham & Women's Hospital - Boston MA
T Cell Sciences, Inc. - Needham MA
International Classification:

A01N 3718
C07K 14705
US Classification:

514 2
Abstract:

Human complement receptor type 1 (CR1). Nucleic acid molecules encoding full-length CR1 protein and fragments thereof having complement regulatory activity are described, as well as recombinant CR1 protein and polypeptides, vectors for their expression, and cell lines expressing or bearing DNA molecules encoding such proteins and polypeptides, including a soluble CR1 polypeptide consisting of the extracellular 30 short consensus repeat domains of the mature CR1 protein. The nucleic acids and polypeptides described are useful in diagnosis and treatment of disorders involving complement activity and inflammation. Compositions useful in therapeutic applications are also disclosed.

Nucleic Acids Encoding A Human C3B/C4B Receptor (Cr1)
view source
US Patent:

52120716, May 18, 1993
Filed:

Apr 3, 1989
Appl. No.:

7/332865
Inventors:

Douglas T. Fearon - Baltimore MD
Lloyd B. Klickstein - Brookline MA
Winnie W. Wong - Newton MA
Gerald R. Carson - Wellesley MA
Michael F. Concino - Newton MA
Stephen H. Ip - Sudbury MA
Savvas C. Makrides - Bedford MA
Assignee:

The Johns Hopkins University - Baltimore MD
Brigham and Women's Hospital - Boston MA
T Cell Sciences, Inc. - Cambridge MA
International Classification:

C12N 1512
C12N 1563
US Classification:

435 691
Abstract:

The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.

Human C3B/C4B Receptor (Cr1)
view source
US Patent:

63166046, Nov 13, 2001
Filed:

Jun 5, 1995
Appl. No.:

8/463959
Inventors:

Douglas T. Fearon - Baltimore MD
Lloyd B. Klickstein - Brookline MA
Winnie W. Wong - Newton MA
Gerald R. Carson - Wellesley MA
Michael F. Concino - Newton MA
Stephen H. Ip - Sudbury MA
Savvas C. Makrides - Bedford MA
Henry C. Marsh - Reading MA
Assignee:

Avant Immunotherapeutics, Inc. - Needham MA
International Classification:

C07K 14435
C12N 1512
US Classification:

530416
Abstract:

The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.

Method Of Treating Complement Mediated Disorders
view source
US Patent:

54729394, Dec 5, 1995
Filed:

Oct 19, 1993
Appl. No.:

8/138825
Inventors:

Douglas T. Fearon - Baltimore MD
Lloyd B. Klickstein - Brookline MA
Winnie W. Wong - Newton MA
Gerald R. Carson - Wellesley MA
Michael F. Concino - Newton MA
Stephen H. Ip - Sudbury MA
Savvas C. Makrides - Bedford MA
Henry C. Marsh - Reading MA
Assignee:

The Johns Hopkins University - Baltimore MD
The Brigham and Women's Hospital - Boston MA
T Cell Sciences, Inc. - Needham MA
International Classification:

A61K 3700
US Classification:

514 8
Abstract:

The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.

Inhibition Of Cxcr4 Signaling In Cancer Immunotherapy
view source
US Patent:

20150352208, Dec 10, 2015
Filed:

Aug 18, 2015
Appl. No.:

14/828729
Inventors:

- Cambridge, GB
Douglas Fearon - Lloyd Harbor NY, US
International Classification:

A61K 39/395
Abstract:

The inventions describes a method for increasing effector T cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of CXCR4 signaling.